〈Case Reports〉Recognition of complete response by long-term observation after treatment with ^<90>Y-Ibritumomab tiuxetan for relapsed follicular lymphoma

• Tatsumi Yoichi

• Rai Shinya

• Shimada Takahiro

• Yamaguchi Terufumi

• Morita Yasuhiro

• Kawanishi Kazunobu

• Miyatake Junichi

• shida Takashi

• Maeda Yasuhiro

• Hosono Makoto

• Matsumura Itaru

Abstract

[Abstract] Monoclonal antibodies have markedly changed the treatment possibilities for patients with indolent B-cell lymphoma. ^<90>Y-Ibritumomab tiuxetan (Zevalin) is the first radioimmunotherapy (RIT) agent approved for the treatment of relapsed and refractory indolent lymphoma patients. In most cases, the maximum clinical response were observed two to three months after RIT. Treatment with ^<90>Y-ibritumomab tiuxetan may have potential late effects in some cases of relapsed follicular lymphomas, and we must be careful to start the next treatment after RIT.

Journal

• Acta Medica Kinki University

  Acta Medica Kinki University 36 (2), 87-89, 2011-12-01

  The Kinki University Medical Association

Keywords

• follicular lymphoma
• ibritumomab tiuxetan
• rituximab
• CD20 antigen
• positron emission tomography

Details

• CRID: 1572543027523888256
• NII Article ID: 120005736804
• ISSN: 03866092
• Web Site: http://id.nii.ac.jp/1391/00010536/
• Text Lang: en
• Data Source:
  • CiNii Articles